Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis

被引:0
作者
Jeanna Wallenta Law
Alicyn Campbell
Colin Weller
Colden Johanson
Ronda Broome
Elisabeth Piault
Monika Izano
Andrew Schrag
Mary Tran
Thomas D. Brown
Henry G. Kaplan
机构
[1] Syapse,
[2] AstraZeneca,undefined
[3] Swedish Cancer Institute,undefined
来源
Breast Cancer Research and Treatment | 2022年 / 196卷
关键词
Metastatic breast cancer; HER2-directed therapy; Interstitial lung disease; Real-world; Epidemiology;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:603 / 611
页数:8
相关论文
共 128 条
[1]  
Loibl S(2021)Breast cancer Lancet 397 1750-250
[2]  
Poortmans P(2020)Advanced approaches to breast cancer classification and diagnosis Front Pharmacol 11 632079-62
[3]  
Morrow M(2020)Towards personalized treatment for early stage HER2-positive breast cancer Nat Rev Clin Oncol 17 233-128
[4]  
Denkert C(2011)HER2: biology, detection, and clinical implications Arch Pathol Lab Med 135 55-30
[5]  
Curigliano G(2019)HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance Ther Adv Med Oncol 11 1758835919833519-366
[6]  
Zubair M(2015)Targeting HER2 for the treatment of breast cancer Annu Rev Med 66 111-1327
[7]  
Wang S(2015)Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 26 v8-1594
[8]  
Ali N(2018)Herceptin(R) (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis Syst Rev 7 191-39
[9]  
Goutsouliak K(2019)Recognizing radiation therapy-related complications in the chest Radiographics 39 344-117
[10]  
Veeraraghavan J(2020)Assessment of immune-related interstitial lung disease in patients with NSCLC treated with immune checkpoint inhibitors: a multicenter prospective study J Thorac Oncol 15 1317-720